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A B S T R A C T
New mixed cationic liposomes based on L-α-phosphatidylcholine and dihexadecylmethylhydrox-
yethylammonium bromide (DHDHAB) were designed to overcome the BBB crossing by using the intranasal
route. Synthesis and self-assembly of DHDHAB were performed. A low critical association concentration (0.01
mM), good solubilization properties toward hydrophobic dye Orange OT and antimicrobial activity against
gram-positive bacteria Staphylococcus aureus (MIC=7.8 μgmL–1) and Bacillus cereus (MIC=7.8 μgmL–1), low
hemolytic activities against human red blood cells (less than 10%) were achieved. Conditions for preparation of
cationic vesicles and mixed liposomes with excellent colloidal stability at room temperature were determined.
The intranasal administration of rhodamine B-loaded cationic liposomes was shown to increase bioavailability
into the brain in comparison to the intravenous injection. The cholinesterase reactivator, 2-PAM, was used as
model drug for the loading in cationic liposomes. 2-PAM-loaded cationic liposomes displayed high encapsulation
eﬃciency (∼ 90%) and hydrodynamic diameter close to 100 nm. Intranasally administered 2-PAM-loaded ca-
tionic liposomes were eﬀective against paraoxon-induced acetylcholinesterase inhibition in the brain. 2-
PAM−loaded liposomes reactivated 12 ± 1% of brain acetylcholinesterase. This promising result opens the
possibility to use marketed positively charged oximes in medical countermeasures against organophosphorus
poisoning for reactivation of central acetylcholinesterase by implementing a non-invasive approach, via the
"nose-brain" pathway.
1. Introduction
Intranasal route remains one of the elective non-invasiveness routes
for the treatment of brain diseases [1]. It is highly appealing in clinical
settings due to rapid central action of drug. This expands drug eﬃ-
ciency in emergency treatment [2]. The nasal mucosa allows direct
delivery of drugs to the brain bypassing the blood brain barrier (BBB). It
avoids hepatic clearance and drug degradation by liver enzymes, and
therefore, increases the eﬀect of neurotherapy [3]. Applicability of in-
tranasal route is limited by lipophilicity and molecular weight of drugs
[4]. New formulations to maximize the concentration of drugs and new
devices for intranasal administration have been developed [5]. To im-
prove drug transfer to the brain and to prolong the residence time of
drug in the nasal cavity, several strategies may be employed, namely
the use of (i) permeation enhancers, muco-adhesive and heat sensitive
gels, or (ii) nano-sized drug carriers. Colloidal nanosized carriers are
especially important for brain delivery and targeting of drugs for
treatment of neurodegenerative diseases [6]. Intranasal delivery to the
brain by using nanosized particles can be carried out for small mole-
cules, as well as for proteins, hormones, vaccines, DNA, etc. [7–10]. The
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